Literature DB >> 15043542

Transpupillary thermotherapy for idiopathic subfoveal choroidal neovascularization.

Atul Kumar1, Gunjan Prakash, Rajindra P Singh.   

Abstract

PURPOSE: To assess the efficacy of transpupillary thermotherapy (TTT) for the management of idiopathic subfoveal choroidal neovascularization (CNV).
METHODS: This was a prospective, non-controlled, clinical case trial involving 21 eyes of 21 patients with a mean age of 36 years. All 21 eyes had idiopathic subfoveal CNV and were subjected to diode laser TTT. Laser beam size ranged from 1.2 mm to 3.0 mm and power settings ranged between 300 mW and 600 mW. The end-point was an area of no visible colour change. Pre- and post-laser evaluations of ETDRS visual acuity, contrast sensitivity, slit-lamp biomicroscopy and fluorescein angiography were carried out.
RESULTS: The nine predominantly occult and 12 predominantly classic subfoveal membranes were followed-up for a mean of 5.1 months after TTT. Overall, 17 eyes (81%) showed improvement or stabilization in ETDRS visual acuity. Contrast sensitivity improved in 17 eyes (81%). Reading speed improved in 15 eyes (71%). Retreatment was needed in three eyes (14%).
CONCLUSION: Transpupillary thermotherapy treatment is a potential strategy for treating idiopathic subfoveal CNV in both its classic and occult forms.

Entities:  

Mesh:

Year:  2004        PMID: 15043542     DOI: 10.1046/j.1600-0420.2004.00217.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand        ISSN: 1395-3907


  3 in total

1.  A case of idiopathic choroidal neovascular membrane in a young patient.

Authors:  M A Khan; Shabnam Bhalla; V S Gurunadh; V K Mohindra; Sridhara Reddy
Journal:  Med J Armed Forces India       Date:  2015-02-16

2.  Idiopathic choroidal neovascular membrane in a young female.

Authors:  Saad Abdullah Waheeb; Mahmood Jameel Showail
Journal:  Oman J Ophthalmol       Date:  2009-09

3.  Intravitreal triamcinolone with transpupillary therapy for subfoveal choroidal neovascularization in age related macular degeneration. A randomized controlled pilot study [ISRCTN74123635].

Authors:  Ricardo Agurto-Rivera; Jose Diaz-Rubio; Luis Torres-Bernal; Tamer A Macky; Juner Colina-Luquez; Gabriela Papa-Oliva; Rama D Jager; Susana Martinez-Jardon; Jans Fromow-Guerra; Hugo Quiroz-Mercado
Journal:  BMC Ophthalmol       Date:  2005-11-25       Impact factor: 2.209

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.